Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma
BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine
Terms and Conditions·Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin.
Email:uservice@ttm.financial